SEC Form 4 · accession 0001209191-19-004773
Entasis Therapeutics Holdings Inc. · ETTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Manoussos Perros
Officer — President and CEO · Director
Period of report
Jan 18, 2019
Accepted (ET)
Jan 22, 2019 · 5:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001724344
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $5.66 | Jan 18, 2019 | A | 123,500 | A | — | Jan 17, 2029 | Common Stock | 123,500 | 123,500 | D |
Explanation of responses
- F1Twenty-five percent (25%) of the shares subject to the option shall vest on January 1, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.